To the full analysis
Alkem Laboratories stock: growth
ALKEM.NSAlkem Laboratories reported $1.56B in revenue for fiscal 2026, up 14.9% on the prior year, up 11% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
16.1%
per year from 2010 to 2026, per share 16.1%
Earnings (Annual rate)
15.3%
per year from 2010 to 2026, per share 15.3%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2010 | |
|---|---|---|---|
| Revenue | 11.0% | 11.7% | 16.1% |
| Revenue per share | 11.0% | 11.7% | 16.1% |
| Earnings | 7.7% | 12.0% | 15.3% |
| Earnings per share | 7.7% | 12.0% | 15.3% |
| Free cash flow | 4.7% | 11.1% | no data |
| Free cash flow per share | 4.7% | 11.1% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $142.84M | $24.98M | −$11.92M |
| 2011 | $175.64M | $34.38M | $76.61M |
| 2012 | $203.98M | $45.22M | −$9.64M |
| 2013 | $242.03M | $52.73M | $35.37M |
| 2014 | $326.95M | $46.66M | $19.8M |
| 2015 | $394.63M | $41.62M | $19.91M |
| 2016 | $517.14M | $78.82M | $49.81M |
| 2017 | $596.94M | $94.81M | −$18.46M |
| 2018 | $670.01M | $67.06M | −$44.4M |
| 2019 | $772.28M | $80.83M | $26.62M |
| 2020 | $870.71M | $119.79M | $23.59M |
| 2021 | $927.73M | $168.47M | $113.73M |
| 2022 | $1.12B | $174.91M | $82.07M |
| 2023 | $1.22B | $104.61M | $154.07M |
| 2024 | $1.32B | $190.87M | $179.5M |
| 2025 | $1.36B | $230.17M | $131.5M |
| 2026 | $1.56B | $244.65M | $143.04M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 25 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.